Nakano Satoko, Sakamoto Haruko, Ohtsuka Masahiko, Mibu Akemi, Sakata Hitomi, Yamamoto Masahiro
Department of Surgery, Kawaguchi Municipal Medical Center, Kawaguchi-city, Saitama, Japan.
Breast Cancer. 2007;14(3):292-6. doi: 10.2325/jbcs.14.292.
The Mammotome is a diagnostic tool used under stereotactic or with ultrasound guidance. A clear indication for Mammotome use under stereotactic guidance is when a non-palpable microcalcification is a target. However, the indications for the use of the Mammotome under ultrasound guidance vary among institutions, and it is difficult to find a place for the Mammotome among conventional biopsy techniques. The Mammotome biopsy has been available in our hospital since July 1999. We assessed the effectiveness and indications of ultrasound-guided Mammotome biopsy.
We performed Mammotome biopsies in 433 cases requiring histological diagnosis from July 1999 to September 2006, using an 11-gauge articulated arm-type Mammotome under ultrasound guidance. There were 377 mass lesions including 83 non-palpable cases and 56 hypoechoic lesions.
The indications for Mammotome biopsy were 162 cases with inconsistent fine needle aspiration (FNA) and imaging findings, 114 cases indeterminate by FNA, 68 cases of an identified pathological type before neoadjuvant chemotherapy and confirmation of hormone receptor status, 36 inadequate cases by FNA, 20 cases of confirmation of fibroadenoma and other benign tumors, 8 removal cases of fibroadenoma, 8 microcalcification cases, and 17 others. The target lesion was obtained in 99.5% of the cases.
Ultrasound-guided Mammotome biopsy is an accurate and useful diagnostic method that enables sufficient amounts of tissue to be obtained with minimal invasion and few complications. The Mammotome is the first choice for obtaining a definitive pathological diagnosis in breast lesions.
麦默通是一种在立体定位或超声引导下使用的诊断工具。在立体定位引导下使用麦默通的明确指征是不可触及的微钙化灶作为目标。然而,超声引导下麦默通的使用指征在不同机构之间存在差异,并且很难在传统活检技术中为麦默通找到一席之地。自1999年7月以来,我院已开展麦默通活检。我们评估了超声引导下麦默通活检的有效性和指征。
1999年7月至2006年9月,我们在超声引导下使用11号关节臂式麦默通对433例需要组织学诊断的患者进行了麦默通活检。其中有377个肿块病变,包括83个不可触及的病例和56个低回声病变。
麦默通活检的指征包括162例细针穿刺抽吸(FNA)与影像学结果不一致的病例、114例FNA结果不明确的病例、68例新辅助化疗前确定病理类型并确认激素受体状态的病例、36例FNA取材不足的病例、20例确诊纤维腺瘤和其他良性肿瘤的病例、8例纤维腺瘤切除病例、8例微钙化病例以及17例其他病例。99.5%的病例获取到了目标病变。
超声引导下麦默通活检是一种准确且有用的诊断方法,能够以最小的侵袭和极少的并发症获取足够量的组织。麦默通是获取乳腺病变明确病理诊断的首选方法。